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Determining the role of IL-4 induced
neuroinflammation in microglial activity and
amyloid-β using BV2 microglial cells and APP/PS1
transgenic mice
Clare H Latta1,5, Tiffany L Sudduth1, Erica M Weekman1,2, Holly M Brothers1, Erin L Abner1,3, Gabriel J Popa4,
Michael D Mendenhall4, Floracita Gonzalez-Oregon1,2, Kaitlyn Braun1,2 and Donna M Wilcock1,2,6*
Abstract
Background: Microglia are considered the resident immune cells of the central nervous system (CNS). In response
to harmful stimuli, an inflammatory reaction ensues in which microglia are activated in a sequenced spectrum of
pro- and antiinflammatory phenotypes that are akin to the well-characterized polarization states of peripheral
macrophages. A “classically” activated M1 phenotype is known to eradicate toxicity. The transition to an “alternatively”
activated M2 phenotype encompasses neuroprotection and repair. In recent years, inflammation has been considered
an accompanying pathology in response to the accumulation of extracellular amyloid-β (Aβ) in Alzheimer’s disease
(AD). This study aimed to drive an M2a-biased immune phenotype with IL-4 in vitro and in vivo and to determine the
subsequent effects on microglial activation and Aβ pathology.
Methods: In vitro, exogenous IL-4 was applied to BV2 microglial cell cultures to evaluate the temporal progression of
microglial responses. In vivo, intracranial injections of an adeno-associate-virus (AAV) viral vector were performed to
assess long-term expression of IL-4 in the frontal cortex and hippocampus of Aβ-depositing, APP/PS1 transgenic mice.
Quantitative real-time PCR was used to assess the fold change in expression of biomarkers representing each of the
microglial phenotypes in both the animal tissue and the BV2 cells. ELISAs quantified IL-4 expression and Aβ levels.
Histological staining permitted quantification of microglial and astrocytic activity.
Results: Both in vitro and in vivo models showed an enhanced M2a phenotype, and the in vivo model revealed a trend
toward a decreased trend in Aβ deposition.
Conclusions: In summary, this study offers insight into the therapeutic potential of microglial immune response in AD.
Keywords: Inflammation, Alzheimer’s disease, Microglia, Beta-amyloid
Introduction
Alzheimer’s disease (AD) was first identified in 1907 by
Alois Alzheimer when investigating the case of a female
patient, Auguste D, suffering from irrational personality
changes and severe memory impairment. Post mortem
analysis revealed a severely atrophied brain, and histological
staining revealed amyloid-β (Aβ) plaques and neurofibrillary
tangles composed of hyperphosphorylated and aggregated
tau. In addition, Alzheimer noted a proliferated cluster of
immune regulatory and support cells surrounding the Aβ
plaques and termed this “gliose”, now known as the inflam-
matory response “gliosis” [1]. This observation signified a
potential interaction between immune regulation and the
development Aβ lesions, a critical relationship that had
previously been understudied until the last 2 decades [2].
Inflammation, the final pathology of the triad, marks the
body’s protective response to detrimental stimuli and injury.
To date, an abundance of studies has confirmed the role of
inflammation in the pathological progression of AD [3].
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Derived from a mesodermal myeloid origin, microglia
act in parallel to their sister immune regulatory cells of the
periphery, macrophages, in the central nervous system
(CNS) [4]. Current understanding of microglial physiology
and activity, including phenotypic diversity, has been
extrapolated. In response to immune stimulation, a spectrum
of macrophage phenotypes is unveiled [5,6]. M1 activation,
or classical activation, is considered the first line of
defence to eradicate invading pathogens and is both
driven and characterized by the release of proinflammatory
cytokines such as interleukin 1β (IL1β) and tumor necrosis
factor α (TNFα). On the other side of the spectrum, M2
activation, or alternative activation, is associated with
wound repair and healing, as well as the ability to dampen
the M1 response [7-10]. M2 activation is broken into
additional sub-categories. M2a activation is characterized
by the expression of mannose receptor MRC1 and
extracellular matrix modeling ability with the expression of
chitinase 3-like 3 proteins (YM1 in mice CHL3 in humans)
and arginase 1, ARG1. Sequentially, acquired “deactivation”
of the immune response is achieved by an M2c phenotype
upon interleukin 10 (IL-10) exposure with amplified
expression of transforming growth factor β1 (TGFβ1)
and sphingosine kinase 1 (SPHK1). The role of an M2b
phenotype is relatively unknown. Nonetheless, it has been
defined by an elevated expression of the CD86 and major
histocompatibility complex II (MHCII) receptors in
comparison to the low constitutive expression of these
receptors across all activation phenotypes [7,10].
An intricate cytokine network tightly controls the
amplification and reduction of each of the microglial
states. IL-4 is considered to be the strongest polarizing
cytokine toward an M2a response [11]. IL-13 has also been
noted as an M2a polarizing cytokine. The interaction of an
M2a phenotype with Aβ remains unclear. The induction of
an M2a phenotype via IL-4 exposure has indicated both
attenuation and amelioration of the neurotoxic peptide
depositions in conflicting in vivo studies [12,13].
To assess M2a-driven modulation of microglial activation,
IL-4 was endogenously applied to BV2 microglial cells and
temporal changes in phenotype and morphology were mon-
itored. Results revealed a robust M2a phenotype peaking at
8 h for the majority of phenotypic markers. Amplification
of alternative phenotypic genes also revealed a peak in
expression suggesting a minutely heterogeneous phenotype.
Morphology showed reduced extended process upon IL-4
application, with the effects dampened over time and
extended process formation. In order to better understand
the effect of an M2a phenotype on Aβ deposition, bilateral
injections of an adeno-associated virus (AAV) expressing
IL-4 were inserted into the frontal cortex and hippocampus
of APP/PS1sw mice. A robust M2a phenotype was success-
fully induced with the AAV IL-4 injection. Histological
staining revealing increased microgliosis and astrogliosis in
the AAV-IL-4 injected mice. Lastly, Aβ levels measured
biochemically were moderately reduced in comparison to
the mice treated with AAV-GFP, therefore providing
insight into a potential mechanism of ameliorating Aβ
pathology in AD.
Material and methods
BV2 cell culture
BV2 cells were obtained from Dr. Linda Van Eldik,
University of Kentucky, Lexington, KY. Cells were grown
on six-well plates in FX12 media containing 10% fetal
bovine serum, 1% serum L-glutamate and 1% streptomycin
(Life Technologies, Carlsbad, CA) until 80% confluency was
obtained approximately 3 days after passage. Cells were
starved of serum for 24 h prior to treatment. Cells were
stimulated with an exogenous application of murine IL-4
(20 ng/ml; R & D Systems, Minneapolis, MN) in the
serum-free medium added to the culture. Serum-free
medium was applied as the no treatment control. Cells were
incubated (5% CO2, 37°C) for 2, 4, 6, 8, 10, 16 and 24 h
before removal. Media were aspirated, and cells were rinsed
twice in Dulbecco’s phosphate-buffered saline pH 7.4
(DPBS) (Life Technologies, Carlsbad, CA) at a 1× dilution
for 5 min and frozen at −80°C. Cell culture experiments
were performed in triplicate and repeated at least three
times at different passage numbers.
Immunofluorescent staining
BV2 cells were grown on glass coverslips in 12-well
plates until 80% confluency after approximately 3 days
from passage. Twenty-four hours prior to the experiment,
cells were starved and treated as above. After incubation
cells were rinsed in 1× DPBS, transferred to a clean
12-well plate, fixed in 10% neutral buffered formalin
(Sigma-Aldrich, St Louis, MO) for 20 min and rinsed
twice in 1× DPBS for 5 min. Cells were blocked in
0.019% L-lysine, 0.3% triton-X (Sigma-Aldrich, St Louis,
MO) and 4% goat serum (Pel-Freez, Rogers, AR) in DPBS
for 45 min and incubated in primary antibody CD11b
1:500 (Rat monoclonal, AbD Serotec, Raleigh, NC) in
1× DPBS overnight at 4°C. Cells were left to acclimate to
room temperature for 1 h and rinsed twice in 1× DPBS
for 5 min before incubation in secondary goat anti-rat
(488 nm) at a 1:20,000 dilution of for 1 h. Glass coverslips
were rinsed twice in 1× DPBS prior to adhesion to
microscope slides using Permafluor mountant (Thermo
Scientific, Fremont, CA). Fluorescence was visualized using
Nikon Elements BR image analysis system (Melville, NY)
at 60× magnification. The same settings were applied to all
of the images.
Animals
This study was approved by the University of Kentucky
Institutional Animal Care and Use Committee and
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conformed to the National Institutes of Health Guide
for the Care and Use of Animals in Research. Fourteen
APP/PS1 transgenic mice [14], a C57BL6 strain of mice
with human APPSwe and PS1-dE9 mutations, were bred
in the Division of Laboratory Animal Resources (DLAR)
at the University of Kentucky and aged for 3 months
prior to surgery. The animals were randomly assigned
into one of two groups for adeno-associated virus type 8
(AAV-8) injection, either the AAV-GFP control group
(N = 8) or the AAV-IL-4 group (N = 6). Data revealed no
gender-dependent differences and were therefore ana-
lyzed together. Mice were killed 43 days post-surgery
because of increased deaths in the IL-4-AAV-injected
animals.
AAV preparation
The vector for preparing recombinant AAV was con-
structed by ligating the 1,349-bp EcoRI/SalI fragment
carrying the IRES-GFP from pSMPUW-IRES-GFP
(Cell Biolabs) into EcoRI/SalI-digested pZac2.1 (gift of
Dr. Paul Murphy, University of Kentucky) to create
ViCo1.28. The IL-4 insert was prepared by polymerase
chain reaction (PCR) amplification of cDNA clones
obtained from Open Biosystems (GE Healthcare,
Dharmacon RNAi and gene expression, Piscataway, NJ).
The IL-4 PCR primer sequence used was ‘CCCGCTAGCG
ACGGCACAGAGCTATTG.
CCACCGCGGGGCTCAGTACTACGAGTA’ (Open
Biosystems, GE Healthcare, Lafayette, CO; Cat. no.:
MMM1013-7510313, clone ID 3376587 and accession
BC027514). The primers introduced a NheI site at the
5′-end and a SacII site at the 3′-end of each cytokine
gene to facilitate cloning into the corresponding sites
in ViCo1.28. The fidelity of each clone was confirmed
by DNA sequence analysis.
AAV-8 coat protein-pseudotyped AAV-2 viruses were
prepared by co-transfecting 10 T225 culture flasks of
293LTV cells (Cell Biolabs) with 250 mg pAAV2/8 (obtained
from the University of Pennsylvania Viral Core), 500 mg
pAdDF6 (gift of Dr. Paul Murphy, University of Kentucky)
and, individually, 250 mg of each cytokine clone using 5 mg
polyethyleneimine to enhance DNA uptake. After 3 days,
the cells were harvested, washed, suspended in 13 ml
150 mM NaCl, 50 mM Tris · Cl pH 8.4, 0.5% deoxycholate
and 50 U/ml of benzonase and incubated at 37°C for
30 min. An additional 2.8 ml 5 M NaCl was added, and the
incubation was continued for another 30 min at 45°C. The
cell suspension was then subjected to four freeze/thaw
cycles (30 min at −80°C/ 30 min at 45°C). The lysate was
then partially clarified by centrifugation at 18,500 × g for
10 min at 20°C. The supernatant was laid on top of an
iodixanol step gradient and centrifuged at 350,000 × g
for 1 h at 18°C. The interface between the 40% and
54% iodixanol layers was withdrawn and spin-purified
and concentrated using four washes with PBS in an
Amicon Ultra-15 100,000 MWCO spin concentrator.
The virus preparation was then titered using real-time
PCR with primers directed against the CMV promoter
region of the DNA encapsulated in the virions.
Bilateral intracranial injections
Mice were anesthetized with 5% isoflurane (Butler-Schein,
Dublin OH) with oxygen levels kept at 1 L/minute and
immobilized in stereotaxic apparatus. They were then
maintained for the duration of surgery between 1% and
2% isoflurane. The skin was shaved and sterilized with a
series of iodine and ethanol treatments before the cranium
was exposed by a mid-sagittal incision. Four burr holes
were made over the frontal cortex and hippocampus of
both the left and right hemispheres using a dental drill
mounted onto a stereotaxic frame. The coordinates for
injection were confirmed by our laboratory prior to the
study using a dye to visualize placement. Using bregma as
the origin, burr holes were made in the frontal cortex
(+2.0 mm anteroposterior, ±2.0 mm lateral) and in the
hippocampi (−2.7 mm anteroposterior, ±2.5 mm lateral)
(as shown in Figure 1). At each of these sites, a 10-μl
Hamilton syringe fitted with a 26-guage needle was lowered
to −3.0 mm ventral to bregma (Hamilton, Reno, NV). Then
2 μl of either AAV-GFP or AAV-IL-4 at a concentration of
5× 1010 genomes/μl was administered over a 2-min period
at each injection site. The mid-sagittal incision was cleaned
and sutured, and a 4% lidocaine ointment was applied.
Animals were group housed, based on sex, under standard
vivarium conditions. Sutures were removed 10 days
post-surgery.
Tissue processing
After 43 days post-surgery, the mice were administered
a lethal intraperitoneal injection of 0.5 ml of Buthanasia-D
(Butler-Schein, Dublin OH) and intracardially perfused with
25 ml 0.9% saline (Ricca Chemical Co., Arlington, TX). The
brain was removed immediately and bisected along the
mid-sagittal plane. The left hemisphere was post-fixed in
4% paraformaldehyde for 24 h before being treated for
cyroprotection through a series of 10, 20 and 30% sucrose
concentrations each for an additional 24 h. The left
hemisphere was placed on a frozen stage and sectioned into
25-μm horizontal sections, which were collected using a
sliding microtome. The sections were stored free-floating in
1× DPBS plus sodium azide at 4°C. Sections were stored in
24-well plates at 4°C until required. The frontal cortex and
hippocampus of the right hemisphere were micro-dissected,
snap-frozen in liquid nitrogen and stowed at −80°C.
Immunohistochemistry
A Nissl stain was used to determine the injection site
location determined as previously described [15]. Eight
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free-floating 25-μm sections spaced ~400 μm from each
other were collected 1,300-3,400 μm ventral to bregma
and separated into 1× DPBS. Initially, the free floating
sections were permeabilized, and endogenous peroxidase
sites were inhibited via incubation with 10% methanol and
3% hydrogen peroxide in 1× DPBS for 15 min. Sections
were blocked with 0.3% triton-X, 4% goat serum and
0.019% L-lysine in 1× DPBS. Sections were incubated in
primary antibodies CD11b, 1:3,000 (Rat monoclonal,
AbD Serotec, Raleigh, NC) and GFAP, 1:10,000, (Rabbit
polyclonal, Dako, Denmark) with 4% goat serum in DPBS
left at room temperature and then overnight at 4°C. After
incubation and three 5-min washes in 1× DPBS, sections
were incubated in biotinylated secondary antibodies; goat
anti-rabbit IgG was used for GFAP and goat anti-rat for
CD11b, both at 1:3,000 (Vector Laboratories, Burlingame,
CA) for 2 h. Amplification of the secondary antibody
signal was achieved through incubation in advidin-biotin
complex (ABC) (Vector Laboratories, Burlingame, CA)
for 1 h. For color development the vector diaminobenzidine
(DAB) peroxidase kit (Vector Laboratories, Burlingame,
CA) was used according to the manufacturer’s instructions.
Sections were mounted onto slides, left to air-dry overnight,
dehydrated in an ethanol gradient followed by xylene incu-
bations and cover-slipped using DPX mountant (Electron
Microscopy Sciences, Hatfield, PA).
Images of the stained sections were taken at 200×
magnification using the Nikon Elements BR image
analysis system (Melville, NY) in the frontal cortex
(FCX). Hippocampal fields were localized to the dentate
gyrus (DG), cornu ammonis 1 (CA1) and cornu ammonis
3 (CA3) and images collected at the same magnification.
Anatomical structures in the tissue were used to ensure
uniformity in the image. Microscope settings were saved
and were the same for all of the images in each stain. A
threshold for positive immunostaining was set, saved and
applied to all of the images of a given stain. The data
yielded the percentage of binary area occupied by the
AAV-GFP AAV-IL-4
CA3
DG
B
C D
E F
A
CA1
Figure 1 IL-4 shows increased CD11b immunostaining. A and B CD11b staining of hippocampal sections of the AAV-GFP- and the
AAV-IL-4-injected mice, respectively. C and D Staining in the dentate gyrus (DG); an arrow shows the site of the hippocampal injection. E The percentage
of binary area occupied by the positive immunostain in the hippocampus across all samples; F uses (N = 4) for AAV-IL4 samples because of damage in
the frontal cortex of two AAV-IL-4 mice. *P< 0.05 between the AAV-GFP control (N = 8) and AAV-IL-4 (N= 6).
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positive immunostain. Approximately six sections per
mouse were used for analysis in the hippocampus and
the frontal cortex. Tissue damage in the frontal cortex of
several animals left large holes interfering with quantifica-
tion of the positive immunostain analysis. Therefore,
two mice in the AAV-IL-4 group were exempt from
this analysis.
ELISA measurements
Protein was extracted from the frontal cortex tissue
by homogenization in mammalian protein extraction
reagent (MPER) lysis buffer with protease and phosphatase
inhibitor (Pierce Biotechnology Inc., Rockford, IL). The
samples were centrifuged for 15 min at 10,000 rg at 4°C.
The supernatant was collected as the soluble extract, leav-
ing a pellet of remaining insoluble extract. A Bicinchonic
Acid protein assay kit (BCA) (Pierce Biotechnology Inc.,
Rockford, IL) was performed to obtain the concentration
of the soluble extract according to the manufacturer’s
instructions. The soluble extracts were normalized to the
lowest concentration using the MPER lysis buffer. Then
250 μl of 70% formic acid was added to the insoluble
extract before ultracentrifugation at 47,000 rpm at 4°C for
1 h. The supernatant was collected and neutralized 1:20
with Tris–HCl (pH 11). Additional HCl was added to bring
the sample accurately to pH 7 using a drop pipet. A Meso
Scale Discovery (MSD) 96-Well MULTI-SPOT Human
(6E10) A-beta Triplex Assay (MSD, Gaithersburg, MD)
was performed on both the soluble and insoluble
extractions, according to the manufacturer’s instructions,
to determine the concentrations of Aβ38, Aβ40 and Aβ42.
Murine IL-4 levels in the soluble extracts were detected
using the the Mouse IL-4 Quantikine ELISA kit (R & D
Systems Inc., Minneapolis, MN). All steps followed
the manufacturer’s instructions. A second BCA was
performed on soluble extracts to confirm the protein
concentration, and samples were normalized prior to
the ELISA measurement.
Quantitative real-time RT-PCR
RNA was extracted from the frozen hippocampus of the
right hemisphere by rotor homogenization Bio-Gen
Pro200 (Pro-Scientific, Oxford, CT) in the RNA-Solv
Reagent of the RNeasy tissue kit (Qiagen, Valencia, CA);
the subsequent steps of the extraction were achieved
according to the manufacturer’s instructions. BV2 cell
homogenization RNA was extracted from the BV2 cells
using cell scrapers in RLT buffer of the RNeasy Mini-kit
(Qiagen, Valencia, CA). Again, the subsequent steps of the
extraction were achieved according to the manufacturer’s
instructions. The Biospec-Nano Spectrophotometer
(Shimadzu, Kyoto, Japan) was used to quantify the
nucleic acid concentration in the RNA samples. The
RNA concentrations were standardized to the lowest
concentration with RNAase free water. The standardized
samples were added to the High Capacity RNA-to-cDNA
kit (Applied Biosystems, Foster City, CA) including re-
verse transcriptase, random primers and buffer according
to the manufacturer’s instructions. The cDNA was pro-
duced through a series of heating and annealing cycles in
the Veriti™ 96-well Thermocycler (Applied Biosystems,
Grand Island, NY).
Quantitative real-time RT-PCR was achieved using the
Fast-TaqMan Gene Expression Kit in 96-well plates (Life
Technologies, Carlsbad, CA); 0.5 μl of the cDNA (100 μl
of standardized RNA samples) was diluted with 6.5 μl of
RNAse-free water and added to each well; 1 μl of the
selected gene probe (Life Technologies, Carlsbad, CA)
listed in Table 1 was added to 10 μl of the Fast-TaqMan
reagent and added to each well. Real-time RT-PCR was
performed using the ViiA™7 Real Time PCR system
(Applied Biosystems, Grand Island, NY). All genes
measured were normalized to the constitutively expressed
18S rRNA gene. The gene expression of the AAV-IL-4
mice was compared relative to the AAV-GFP control
group. Fold change was calculated using the 2–ΔΔCt
method [16].
Data analysis
For the in vitro analysis, normalized fold change values
were log-transformed in order to apply parametric
statistical methods. Repeated measures ANOVA, with
an unstructured covariance matrix, was then used to
estimate mean log fold change at each time point
within each gene. The time point at which expression
peaked was determined by post hoc testing such that the
largest point estimate observed was then compared to the
Table 1 Genes for RT-qPCR
Gene of interest PMID Taqman ID
IL-1β NM_008361.3 Mm00434228_m1
IL-12 NM_008351.2 Mm00434165_m1
TNFα NM_013693.3 Mm00443258_m1
IL-6 NM_031168.1 Mm00446190_m1
IFNγ NM_008337.3 Mm01168134_m1
IL1ra NM_031167.5 Mm00446186_m1
ARG1 NM_007482.3 Mm00475988_m1
YM1 (Chil3) NM_009892.2 Mm00657889_mH
FIZZ1 NM_020509.3 Mm00445109_m1
MRC1 NM_008625.2 Mm00485148_m1
CD86 NM_019388.3 Mm00444543_m1
FcγR1 NM_010186.5 Mm00438874_m1
FcγR3 NM_010188.5 Mm00438882_m1
TGFβ1 NM_011577.1 Mm01178820_m1
SPHK1 NM_011451.3 Mm01252544_m1
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*
*
*
A
B
C D
*
Figure 2 The relative gene expression for genes representative of the (A) M1, (B) M2a, (C) M2b and (D) M2c phenotypes of the
IL-4-treated cell culture. Data are shown as the average fold change (± SEM) relative to the no treatment control at the 2-, 4-, 6-, 8-, 10-, 16- and
24-h time points. *The peak time point of gene expression determined by a repeated measures ANOVA of the fold changes in logarithmic form.
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remaining time points. No ties were observed for peak
time (i.e., the largest point estimate was identifiable for
each gene). Repeated measures analyses were performed
using the MIXED procedure in SAS 9.3® (SAS Institute,
Inc., Cary, NC). Otherwise, group differences were
assessed using two-sample Student’s t-tests. Analysis
tests and data representation were performed using
GraphPad Prism version 6.01 for Windows (GraphPad
Software, La Jolla, CA, USA). Statistical significance
was set at 0.05.
Results
To determine the effect of the murine IL-4 application
on BV2 cells, RNA was extracted, and qRT-PCR was
performed on the gene markers specific to each phenotype
(M1, M2a, M2b, M2c) as shown in Figure 2. Fold change
was calculated relative to cell culture exposed to a
no-treatment control. Both IL1β and TNFα of the M1
phenotype show a peak at 8 h (Figure 2A). In the
M2a phenotype, ARG1 is largely amplified to 3,500
fold at 8 h; additionally, MRC1 also peaks at 8 h.
IL1ra shows a significant peak at 10 h post treatment
(Figure 2B). YM1 was found to have aberrant expression in
both the control and IL-4-treated cells and was therefore
exempt from the analysis. No significant differences can be
seen in the M2b phenotype over time (Figure 2C), but we
found elevated levels of Tgfβ1 in the M2c phenotype
(Figure 2D). Table 2 shows the individual P values for the
comparisons of gene expression over the time course.
The morphology of the CD11b-positive BV2 cells over
this time course was monitored by immunofluorescent
staining, shown in Figure 3. Generally, CD11b-positive
microglial cells did not differ after treatment with IL-4
in spite of a clear difference in the inflammatory phenotype.
We did observe a qualitatively decreased density of
extended processes of the BV2 cells in the IL-4-treated
Table 2 P values for individual time-point comparisons
for qRT-PCR in IL-4-treated BV2 cell culture
IL1β 2 4 6 8 10 16 24
2 0.9613 0.3623 0.0024 0.3746 0.0354 0.0218
4 0.4365 0.0270 0.2481 0.0405 0.168
6 0.0122 0.2677 0.0698 0.1067
8 0.4261 0.0024 0.0006
10 0.0792 0.0520
16 0.8212
24
TNFα 2 4 6 8 10 16 24
2 0.2953 0.0987 0.0252 0.9023 0.6955 0.5087
4 0.0095 0.4168 0.5882 0.2381 0.9796
6 0.0372 0.3117 0.1469 0.0680
8 0.3731 0.1441 0.5100
10 0.7412 0.7478
16 0.4097
24
IL1ra 2 4 6 8 10 16 24
2 0.8337 0.2886 0.9078 0.6454 0.2457 0.6626
4 0.2485 0.8572 0.6258 0.2486 0.7000
6 0.7178 0.4069 0.6078 0.2248
8 0.6661 0.5646 0.7672
10 0.3647 0.8656
16 0.2865
24
MRC1 2 4 6 8 10 16 24
2 0.7488 0.3842 0.0007 0.5648 0.5007 0.8252
4 0.1018 0.0025 0.4226 0.3949 0.5433
6 0.0048 0.8499 0.8391 0.5605
8 0.0003 0.0205 0.0083
10 0.7647 0.7846
16 0.6493
24
ARG1 2 4 6 8 10 16 24
2 0.0138 <.0001 <.0001 0.0004 0.0208 0.0085
4 0.0106 0.0020 0.0041 0.4579 0.7186
6 0.0018 0.2438 <.0001 0.0012
8 0.1388 <.0001 <.0001
10 0.0014 0.0156
16 0.1544
24
CD86 2 4 6 8 10 16 24
2 0.2042 0.4318 0.9169 0.5731 0.2545 0.0203
4 0.8782 0.3780 0.8207 0.8871 0.4193
6 0.5538 0.9294 0.8339 0.5795
Table 2 P values for individual time-point comparisons
for qRT-PCR in IL-4-treated BV2 cell culture (Continued)
8 0.6455 0.4060 0.1343
10 0.8108 0.6164
16 0.7600
24
TGFβ1 2 4 6 8 10 16 24
2 0.7553 0.8404 0.0200 0.8186 0.7694 0.2791
4 0.6795 0.1164 0.9889 0.8582 0.0118
6 0.0406 0.8702 0.9094 0.0356
8 0.2138 0.0431 0.0127
10 0.9236 0.1373
16 0.0771
24
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Figure 3 BV2 cell culture exposed to CD11b immunofluorescent staining over time. A-G Immunofluorescent staining of no-treatment
control cells at 2, 4, 6 8, 10, 16 and 24 h, respectively. H-N Staining of cells exposed to the IL-4 treatment at 2, 4, 6, 8 10, 16 and 24 h, respectively.
Images were taken with approximately the same cell confluency at a magnification of 60× and show a higher density of processes in the no
treatment control compared to the IL-4-treated cells until 16 h. Arrow indicates extended processes seen on the untreated BV2 cells at 6 h.
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groups compared to the no-treatment control groups, but
this was not quantifiable (Figure 3).
A sandwich ELISA was performed to confirm that the
AAV-8 was an effective vehicle for gene delivery resulting
in IL-4 expression. Protein extracts taken from the right
frontal cortex showed a marked significant increase
(P = 0.0145) in IL-4 levels (mean 32.2 ng IL-4/mg
protein) in the mice receiving AAV-IL-4 in comparison to
the AAV-GFP-treated mice (mean 2.4 ng IL-4/mg
protein). Figure 4 indicates the neuroinflammatory profile
of the AAV-IL-4 mice relative to that of the AAV-GFP
controls. Real-time qPCR was performed from RNA
extracts from the right hippocampus. Genetic probes were
selected based on their role in M1, M2a, M2b and M2c
phenotypes identified in peripheral macrophages. As
hypothesized, a robust M2a phenotype can be observed
as a result of the AAV-IL-4 injection. IL1ra, YM1, ARG1
and FIZZ1 proved to be significantly different from
the control. In particular, YM1 and FIZZ1 showed a
700–1,000-fold change. Elevated expression of M1-specific
genes can also be identified with significant increases in
IL1β and IL12a.
To determine the morphology and activation of microglia
in response to the AAV-IL-4 treatment, tissue sections
were stained with a β-integrin marker, CD11b. In the
hippocampus, Figure 1A and B shows an increased trend
in positive CD11b immunostaining. In particular, the DG
reveals a positive increase in the positive immunostaining
(Figure 1C and D). An arrow in Figure 1C highlights
microglial activation around the injection site of the
AAV-IL-4 mice. Interestingly, we found increased
CD11b staining in the hippocampus of AAV-IL-4
mice, which was statistically significant in the dentate
gyrus region (Figure 1E), but we did not see changes
in the frontal cortex (Figure 1F).
In addition, immunostaining was conducted with
GFAP to assess the effect of the AAV-IL-4 treatment on
astrogliosis. Figure 5A and B shows a modest increase in
positive immunostaining, exemplified in Figure 5C,
but fails to show any significant results. Once again,
analysis on the frontal cortex was performed on a
sample size of N = 4 in the AAV-IL-4 mice, consist-
ent to that of the CD11b stain. It should be noted
that an increase in astroglial staining could be observed
in the AAV-GFP mice around the hippocampal injec-
tion site.
Aβ depositions in the APP/PS1 transgenic mice were
determined biochemically on the MPER soluble and
insoluble (formic acid soluble) protein extracts. An
MSD ELISA multiplexed assay was used to analyze
the concentration of Aβ 1–38, Aβ 1–40 and Aβ 1–42
in the pg/mg of the protein extract (Table 3). Modest
decreases are shown in both the Aβ soluble extracts
despite no marked significance (Figure 6A). An exception
to this is the Aβ1-42 depositions in the insoluble extract.
Immunostaining for Aβ and Congo red staining proved to
be inconclusive because of the scarce compact plaque
formation due to the young age of the survival of the
mice. Values for the Aβ species concentrations are
given in Table 4.
Discussion
Inflammation and Aβ are suggested to work both
independently and synergistically, contributing to the
development of AD symptoms and pathological pro-
gression [2,17-19]. It remains unknown whether
inflammation has a direct or indirect effect on the
acceleration of Aβ pathology, with data showing both
increased and decreased amyloid deposition [20,21].
The current study aimed to characterize the M2a
response stimulated by IL-4 both in vitro and in vivo.
Further, we investigated the effect of an M2a pheno-
type on Aβ levels in the brain. The time courses of
microglial morphology and phenotypic alterations in
response to the application of IL-4 applied exogenously
were assessed using the immortalized murine microglial
cell line, BV2. In vivo, IL-4 was delivered to the brain
using an AAV vector in the APP/PS1 transgenic mouse
model. IL-4 is a typical inducer of an M2a phenotype [11].
An M2a phenotype was indeed induced following IL-4
application using both in vitro and in vivo approaches.
The BV2 microglial cells showed a time-dependent
heterogeneous phenotype with the M2a response being
the most robust. These results concurred with the in vivo
study; again, an evident M2a phenotype was induced with
depleted Aβ deposits. Unfortunately, due to significant
Figure 4 IL-4 induces an M2a neuroinflammatory phenotype in
APP/PS1 transgenic mice. The figure shows the relative gene
expression for genes representative of the M1, M2a, M2b and M2c
phenotypes relative to the 18-s endogenous control. Data are shown as
the average fold change (± SEM) normalized to the AAV-GFP control.
*P < 0.05 between the AAV-GFP control (N= 8) and AAV-IL-4 mice
(N= 6). **P < 0.01 between the AAV-GFP control and AAV-IL-4 mice.
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death in the mice receiving the IL-4 AAV, we terminated
the study prematurely; thus, our measurement of Aβ
deposition was restricted to biochemical outcomes.
IL-4 was selected as our stimulus for an M2a phenotype
as it has been shown to be the standard stimulator of an
M2a phenotype in peripheral macrophages [11]. Application
of IL-4 onto BV2 cells revealed a robust time-dependent
increase in M2a phenotypic markers with the vast majority
showing a statistically significant peak in expression at 8 h.
Overall, phenotypic expression in IL-4-induced BV2 cells
strongly validates the gene screening seen in the in vivo
model. In addition to the exhibition of a robust M2a state,
increases in M1 and M2c could also be observed indicating
an overall heterogeneous phenotype in response to the IL-4
application. This heterogeneity suggests links between
these markers, emphasizing the spectral nature of
microglial phenotypes and the potential interplay of the
mechanistic actions of downstream pathways. Hence,
further investigations are required to decipher these
cascades. The time course shows that IL1β is increased in
the BV2 cells in direct proportion to the increase in the
IL1ra. It is possible that the increase in IL1ra is a homeo-
static response to counteract amplified expression of IL1β.
IL1β has a diverse range of physiological roles within the
CNS [22]; therefore the benefits of complete antagonism
to achieve an M1 phenotype could be detrimental to
maintaining overall homeostasis within the tissue. In
addition, the M2a phenotypic genes ARG1 and MRC1
both peak at 8 h. Future studies may examine other
mechanisms by which we can promote an M2a response.
For example, IL-13 is also an M2a-promoting cytokine,
overlapping with the IL-4 pathway by dimerization of
the shared IL-4Rα with IL-13Rα1 to activate a STAT-6
mechanism [23].
Immunofluorescent CD11b was used to visualize the
microglial morphology at the sequential time points.
Table 3 Soluble and insoluble Aβ levels measured by ELISA
AAV injection Soluble (pg/μg protein) Insoluble (ng/μg protein)
Aβ-38 Aβ-40 Aβ-42 Aβ-38 Aβ-40 Aβ-42
GFP-AAV 30.6 ± 12.6 80.4 ± 17.7 105.6 ± 26.8 204.6 ± 82.1 191.5 ± 62.6 461.8 ± 96.0
IL-4-AAV 13.2 ± 6.7 60.4 ± 16.3 45.2 ± 8.6 83.0 ± 45.1 62.6 ± 12.1 472.2 ± 181.5
Bold font indicates P < 0.05 compared to GFP-AAV of the same time point.
CA1
CA3
DG
A B
C D
Figure 5 IL-4 shows increased GFAP immunostaining. A and B GFAP staining of hippocampal sections of the AAV-GFP- and the AAV-IL-4-injected
mice, respectively. C The percentage of binary area occupied by the positive immunostain in the hippocampus across all samples; D uses (N = 4) for
AAV-IL4 samples because of damage in the frontal cortex of two AAV-IL-4 mice. *P < 0.05 between the AAV-GFP control (N = 8) and AAV-IL-4 (N = 6).
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CD11b is a microglial surface integrin expressed solely
during activation, and it was previously indicated
that disruption to homeostasis induces an “amoeboid”
retraction of ramified processes, an enlarged cytoplasm,
which is an indication of the activated state [24,25].
Extended filopedia can be seen up until the 6-h time point
in the no-treatment control, suggesting a maintained rest-
ing state as opposed to the retracted and condensed shape
compared to that of the IL-4-treated cells demonstrating
activation. There is no distinct correlation between the
morphology at the time points with the inflammatory
profile despite the minor morphological changes discussed.
Investigation of the inflammatory profile from RT-qPCR
of the right hippocampus of mice injected with IL-4
expressing AAV indicated a robust M2a phenotype
with significant elevations in all inflammatory markers.
Extracellular matrix remodeling proteins YM1 and FIZZ1
showed highly amplified levels reaching 500–1,000 fold.
IL1ra showed a marked increase, neutralizing the role of
IL1β. Congruent to the trend identified in the BV2 cells,
the immune profile also exhibited increases in M1
phenotypic genes, specifically IL1β and IL-12a, sug-
gesting a heterogeneous immune profile with chronic
exposure to IL-4. Furthermore, this exemplifies the
continuum of functionality in which microglia lie. It is
evident that elevation of the M1 phenotype has responsive
ties to that of the M2a phenotype, as seen in the BV2
cells. Phenotypic heterogeneity was further enforced
by Weekman et al. [26], who revealed a mixed phenotype
with IFNγ stimulation after 6 months of exposure. Unlike
the BV2 cells, elevations of an M2b or M2c could not be
observed in the mouse tissue.
CD11b immunohistochemistry is used to visualize
activated microglia generating an indication of gliosis
in a given tissue area. Astrocytes are also considered to have
an immune-regulatory role. GFAP staining visualizes astro-
gliosis, proliferation of astrocytes in a given area. In this
study, the data reveal increases in positive immunostaining
in response to the AAV-IL-4 treatment, indicating a
responsive proliferation of both cell subsets associated
with elevated M2a phenotypic expression. Specifically,
staining with CD11b revealed marked, statistically
significant positive immunostaining in the dentate
gyrus of the hippocampus, suggesting increased micro-
gliosis in this region. Data from the GFAP staining also
show increased immunoreactivity, but there was no statis-
tical significance in any region of the hippocampus or
frontal cortex. What is particularly intriguing is that
these markers of “inflammation” that are presumed to
represent proinflammatory responses are actually sig-
nificantly increased in the presence of the M2a
Table 4 Fold change values for RT-PCR in APP/PS1
transgenic mice
Gene GFP-AAV IL-4-AAV
IL1β 1.20 ± 0.27 4.63 ± 0.67
INFγ 1.20 ± 0.39 1.70 ± 0.32
IL6 1.33 ± 0.40 2.43 ± 0.38
IL12a 1.18 ± 0.31 3.60 ± 1.64
TNFα 0.74 ± 0.51 1.24 ± 0.15
IL1ra 1.41 ± 0.44 16.24 ± 3.62
YM1 1.90 ± 1.04 979.43 ± 251.30
ARG1 1.27 ± 0.40 216.17 ± 65.91
FIZZ1 2.80 ± 1.74 767.81 ± 108.26
CD86 1.19 ± 0.29 1.91 ± 0.36
FCγR1 1.22 ± 0.33 1.23 ± 0.07
FCγR3 1.15 ± 0.26 1.61 ± 0.17
TGFβ1 1.21 ± 0.30 1.62 ± 0.28
SPHK1 1.03 ± 0.10 1.61 ± 0.12
Bold font indicates P < 0.05 compared to GFP-AAV of that time point
and genotype.
Figure 6 IL-4 causes a small decrease in Aβ deposition. This figure shows the relative amyloid-β expression (1–38,1-40,1-42) detected using a
Meso Scale Discovery assay (MSD) for the AAV-GFP control and the AAV-IL-4-treated APP/PS1 transgenic mice. No statistically significant difference
was seen between the AAV-GFP control and AAV-IL-4 groups, but the results show a decreasing trend (N = 8 AAV-GFP and N = 6 for AAV-IL-4).
Immunostained Aβ plaques with Congo red could not be detected because the mice were only 3 months old. Compact plaques can be seen at
6 months of age.
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phenotype, which is often considered “antiinflammatory”.
This may suggest a re-consideration in the field as to
what these immunohistochemical markers functionally
represent.
Data on the effect of the M2a phenotype on amyloid
deposition were inconclusive. We did find a decreasing
trend in Aβ levels in response to the AAV-IL-4 despite
no marked statistical significance. This may have been
due to the premature termination of the study. IL-4 has
been studied in relation to AD pathology with mixed
outcomes. Indeed, a study design very similar to the
current study used AAV to overexpress IL-4 in the
TgCRND8 mouse model. Here, increased amyloid
deposition was observed 6 weeks post injection. Similar to
the current study, enhanced GFAP and CD11b immuno-
histochemistry was also observed [13]. IL-4 has also been
shown to attenuate Aβ-mediated neuroinflammation
in a rat model [27] and promote the clearance of
oligomeric Aβ by microglia in vitro [28]. The conflicting
data highlight the complexities of the neuroinflammatory
response and provide the rationale for further studies
using better agents to chronically stimulate specific
phenotypes.
Understanding the role of inflammation in Alzheimer’s
disease is accelerating within the field. Yet, the direction
at which to target inflammation remains a hot topic of
contention. Overall, the investigation accentuates that
the microglial phenotypic continuum is influenced by
multitude of dimensions. This study has emphasized that
intricate cytokine networks function on a time- and
concentration-dependent scale. Cytokine interplay needs
to be further investigated in detail to maximize the
therapeutic success of immune modulation. Further
studies should address the heterogeneous inflammatory
profile of the AD brain at different stages of progression
across all etiologies and the physiological impacts of
aging on microglial ability to retain their function. In
addition, the complex communications between the dif-
fering glial cells of the CNS should be acknowledged
when targeting the immune response. Taken together,
research in this field should move toward elucidating a
personalized therapeutic approach to treating individual
AD patients.
Conclusions
Our data show that IL-4 induces a robust M2a pheno-
type in microglial cells in both in vitro and in vivo
models with implicating elevations of M1 phenotypic
markers. The M2a inflammatory state is associated with
increased microgliosis and astrogliosis as evidenced by
increased CD11b and GFAP-positive immunostaining.
Additionally, biochemical analysis shows modest reductions
in soluble and insoluble Aβ lengths in APP/PS1sw
transgenic mice at 3 months of age.
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